Novo Nordisk's Wegovy approved in India for fatty liver disease treatment
Novo Nordisk's weight loss drug Wegovy (semaglutide injection 2.4 mg) has received approval from the Central Drugs Standard Control Organization (CDSCO) in India for a new indication: the treatment of non-cirrhotic metabolic dysfunction associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis. This makes Wegovy the first and only GLP-1 RA approved globally and in India for MASH, a liver disease caused by excess fat buildup, chronic inflammation, and liver damage. The approval, alongside a reduced calorie diet and increased physical activity, marks a significant milestone in treating this condition.
Key Points
- Novo Nordisk's drug Wegovy has been approved in India for treating fatty liver disease.
- The approval is for non-cirrhotic metabolic dysfunction associated steatohepatitis (MASH) in adults.
- Wegovy is the first and only GLP-1 RA approved globally and in India for MASH.
- MASH is a liver disease characterized by excess fat buildup, inflammation, and liver damage.
- The treatment is to be used in conjunction with a reduced calorie diet and increased physical activity.
Exam Facts
- Drug name: Wegovy (semaglutide injection 2.4 mg).
- Approved by: CDSCO (Central Drugs Standard Control Organization).
- Indication: non-cirrhotic metabolic dysfunction associated steatohepatitis (MASH).
- Manufacturer: Novo Nordisk.
- MD of Novo Nordisk India: Vikrant Shrotriya.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.